In vitro research and clinical practice also proved that β-elemene can reverse the resistance of tumor cells to a variety of anticancer drugs (Mu et al., 2016) including chemotherapeutics, tyrosine kinase inhibitor gefitinib, etc. However, the target of β-elemene and the effect of reversing the resistance to 5-Fu in p53-deficient colorectal cancer in clinical treatment have not been reported. Here, TP53 is linked to colorectal cancer.